DNA vaccination strategies for anti-tumour effective gene therapy protocols.
After more than 15 years of experimentation, DNA vaccines have become a promising perspective for tumour diseases, and animal models are widely used to study the biological features of human cancer progression and to test the efficacy of vaccination protocols. In recent years, immunisation with naked plasmid DNA encoding tumour-associated antigens or tumour-specific antigens has revealed a number of advantages: antigen-specific DNA vaccination stimulates both cellular and humoral immune responses; multiple or multi-gene vectors encoding several antigens/determinants and immune-modulatory molecules can be delivered as single administration; DNA vaccination does not induce autoimmune disease in normal animals; DNA vaccines based on plasmid vectors can be produced and tested rapidly and economically. However, DNA vaccines have shown low immunogenicity when tested in human clinical trials, and compared with traditional vaccines, they induce weak immune responses. Therefore, the improvement of vaccine efficacy has become a critical goal in the development of effective DNA vaccination protocols for anti-tumour therapy. Several strategies are taken into account for improving the DNA vaccination efficacy, such as antigen optimisation, use of adjuvants and delivery systems like electroporation, co-expression of cytokines and co-stimulatory molecules in the same vector, different vaccination protocols. In this review we discuss how the combination of these approaches may contribute to the development of more effective DNA vaccination protocols for the therapy of lymphoma in a mouse model.
Signori
Emanuela
E
CNR-Institute of Neurobiology and Molecular Medicine, Via Fosso del Cavaliere100, 00133 Rome, Italy. emanuela.signori@cnr.it
Iurescia
Sandra
S
Massi
Emanuela
E
Fioretti
Daniela
D
Chiarella
Pieranna
P
De Robertis
Mariangela
M
Rinaldi
Monica
M
Tonon
Giancarlo
G
Fazio
Vito Michele
VM
D000818:Animals; D019496:Cancer Vaccines; D004195:Disease Models, Animal; D015316:Genetic Therapy; D006801:Humans; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D051379:Mice; D019444:Vaccines, DNA
D019496:Cancer Vaccines; D019444:Vaccines, DNA
Mol Ther. 2008 Dec;16(12):2022-9
18797450
J Immunol. 2005 May 15;174(10):6292-8
15879128
Nat Rev Genet. 2008 Oct;9(10):776-88
18781156
Recent Pat Anticancer Drug Discov. 2009 Nov;4(3):227-40
19522699
Expert Opin Biol Ther. 2008 Nov;8(11):1645-57
18847301
Blood. 2003 Jun 15;101(12):4930-6
12576325
Biochem Biophys Res Commun. 2008 May 30;370(2):279-84
18364239
Cancer Immunol Immunother. 2009 Mar;58(3):317-24
18704409
Nat Rev Drug Discov. 2003 Sep;2(9):727-35
12951579
J Biomed Biotechnol. 2010;2010:174378
20368780
J Gen Virol. 2009 Feb;90(Pt 2):414-422
19141451
Cancer Res. 2001 Feb 15;61(4):1555-62
11245465
J Immunol. 2001 Aug 1;167(3):1558-65
11466377
J Immunol. 1987 Oct 15;139(8):2825-33
3498771
Eur J Immunol. 1989 Dec;19(12):2237-42
2481588
J Clin Invest. 2004 Nov;114(9):1334-42
15520866
Genet Vaccines Ther. 2008 Sep 23;6:13
18811960
Clin Cancer Res. 2000 May;6(5):1678-92
10815886
Cancer Immunol Immunother. 2005 Aug;54(8):721-8
16010587
Clin Cancer Res. 2009 Sep 1;15(17):5323-37
19723653
Haematologica. 2005 Jan;90(1):60-5
15642670
Nat Biotechnol. 2000 Jan;18(1):33-7
10625387
Vaccine. 2009 Aug 27;27(39):5411-8
19616501
Nat Rev Cancer. 2008 Feb;8(2):108-20
18219306
Expert Opin Biol Ther. 2007 Oct;7(10):1551-62
17916047
J Immunol. 2002 Oct 1;169(7):3908-13
12244189
Expert Rev Vaccines. 2007 Oct;6(5):673-84
17931149
J Immunol. 2001 May 1;166(9):5366-73
11313372
J Immunother. 2001 May-Jun;24(3):195-204
11394496
Expert Rev Vaccines. 2008 Sep;7(7):1085-101
18767956
Recent Pat Antiinfect Drug Discov. 2008 Jun;3(2):93-101
18673122
Virology. 2005 Apr 10;334(2):255-63
15780875
Vaccine. 2001 Sep 14;19(32):4652-60
11535313
Eur J Immunol. 1993 Feb;23(2):425-32
7679644
Mol Ther. 2006 Apr;13(4):776-85
16414309
Gene Ther. 2006 Feb;13(3):245-56
16163376
Eur J Immunol. 1990 Mar;20(3):477-83
1690656
J Immunol. 1988 Nov 1;141(9):3227-33
3049819
Curr Opin Biotechnol. 1994 Oct;5(5):505-10
7765464
Curr Opin Oncol. 2005 Sep;17(5):432-40
16093791
Scand J Immunol. 2004 Sep;60(3):219-25
15320877
N Engl J Med. 1992 Oct 22;327(17):1209-15
1406793
Immunol Rev. 2004 Jun;199:156-80
15233733
Infect Immun. 2004 Aug;72(8):4884-7
15271954
Tissue Antigens. 2002 Jun;59(6):443-51
12445314
Gene Ther. 2010 Feb;17(2):261-71
19865176
J Immunol. 2002 Jun 1;168(11):5499-506
12023344
J Biomed Biotechnol. 2010;2010:316069
20445751
Nat Med. 1997 Jun;3(6):625-31
9176488
Front Biosci. 2002 Jan 01;7:d228-34
11779689